Compare · ISPC vs MEDP
ISPC vs MEDP
Side-by-side comparison of iSpecimen Inc. (ISPC) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISPC and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $16.50B, about 4255.1x ISPC ($3.9M).
- MEDP has been more active in the news (11 items in the past 4 weeks vs 4 for ISPC).
- MEDP has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $3.9M
- $16.50B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 4
- 11
- Recent ratings
- 2
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
- E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
Latest MEDP
- President & CEO Troendle August J. sold $403,176 worth of shares (650 units at $620.27), decreasing direct ownership by 0.12% to 539,894 units (SEC Form 4)
- Innventure Announces Board Leadership Changes to Further Enhance Board Independence and Acceleration of CEO Transition
- Director Kraft Robert O. exercised 3,858 shares at a strike of $84.36 and sold $2,383,511 worth of shares (3,858 units at $617.81) (SEC Form 4)
- President & CEO Troendle August J. sold $2,897,636 worth of shares (4,673 units at $620.08), decreasing direct ownership by 0.86% to 540,544 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)